Free paper session - Medical

Chair(s)

• 

  Cedric Hermans, MD, FRCP, PhD (he/him/his)

  Head, Hemophilia Center
  Hematology
  Cliniques Universitaires Saint-Luc
  Brussels, Belgium

Presenter(s)

• 

  David Gutstein, MD (he/him/his)

  Vice President
  Hematology
  Regeneron
• 

  Marilyn Manco-Johnson, MD (she/her/hers)

  Pediatric Hematologist (faculty)
  Pediatrics
  University of Colorado
  Aurora, United States
• 

  Andreas Strauss, PhD

  Executive Senior Physician
  Clinic of Orthopedics and Trauma Surgery
  University Hospital Bonn
• 

  Waander van Heerde, PhD (he/him/his)

  Academic Clinical Assistant, Hematology
  Hematology
  Radboudumc, HTC-NEM
  Nijmegen, Netherlands

Presentations:

• 16:45 - 16:46 ART

  Chair
  

  Chair: Cedric Hermans, MD, FRCP, PhD (he/him/his) – Cliniques Universitaires Saint-Luc
• 16:46 - 16:57 ART

  200 Person Years of Emicizumab: What Bleed-Free Activity can Persons with Hemophilia Expect?
  

  Presenter: Marilyn Manco-Johnson, MD (she/her/hers) – University of Colorado
• 16:57 - 17:09 ART

  The EnzySystem: a tool to introduce Personalized Medicine in Hemophilia A
  

  Presenter: Waander van Heerde, PhD (he/him/his) – Radboudumc, HTC-NEM
• 17:09 - 17:21 ART

  Prevalence of Osteoporosis in Patients with mild, moderate or severe Haemophilia
  

  Presenter: Andreas Strauss, PhD – University Hospital Bonn
• 17:21 - 17:33 ART

  CRISPR/Cas9-Based Gene Editing for Hemophilia B: Durable Pre-Clinical Expression of Factor IX
  

  Presenter: David E. Gutstein, MD (he/him/his) – Regeneron
• 17:33 - 17:45 ART

  Discussion
  

  Chair: Cedric Hermans, MD, FRCP, PhD (he/him/his) – Cliniques Universitaires Saint-Luc